Abstract: It has been reported that Ethaselen shows inhibitory effects on thioredoxin reductase (TrxR) activity and human tumor cell growth. In order to find an efficient way to reverse cisplatin resistance, we investigated the reversal effects of Ethaselen on cisplatin resistance in K562/cisplatin (CDDP) cells that were established by pulse-inducing human erythrocyte leukemic cell line K562, which are fivefold more resistant to cisplatin compared to K562 cells. The morphology and growth showed that the adhesion of K562/CDDP further decreased while the cell volume increased. The proliferation of K562/CDDP is strengthened. The antitumor activities in vitro were assessed by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay and combination index (CI), showing the significant synergic effects of cisplatin and Ethaselen. Focusing on apoptosis, a series of comparisons was made between K562 and K562/CDDP. Cisplatin induced higher reactive oxygen species (ROS) generation in K562 and subsequently induced the formation of mitochondrial permeability transition pores (PTPs). In addition, cisplatin increased the ratio of Bax to Bcl-2 in K562, which can influence the mitochondrial membrane permeability. PTP formation and mitochondrial membrane permeabilization eventually resulted in the release of cytochrome c and activation of the Caspase pathway. However, these effects were not clearly seen in K562/CDDP, which may be the reason for the acquired CDDP resistance. However, Ethaselen can induce a high level of ROS in K562/CDDP by TrxR activity inhibition and increased ratio of Bax to Bcl-2 in K562/CDDP by nuclear factor κB (NF-κB) suppression, which subsequently induces the release of cytochrome c in K562/CDDP. This response is partly responsible for the reversal of the cisplatin resistance in K562/CDDP cells.
Introduction
Cisplatin, a potent antitumor alkylating agent, is widely used for the clinical treatment of many malignancies, such as testicular, ovarian, head and neck, bladder, esophageal, and small cell lung cancers. Cisplatin exerts its anticancer activity by forming 1,2-intrastrand cisplatin-DNA cross-links (Mantri et al., 2007; Yaneva et al., 2007; Harrington et al., 2010) . However, a serious limitation in cancer chemotherapy with cisplatin is the development of drug resistance. Furthermore, the dose escalation required to overcome even a small increase in resistance of a tumor to cisplatin can cause severe toxicities in patients (Yeh and Cheng, 1997; Miyata et al., 2012) . Therefore, understanding the molecular basis of cisplatin resistance and finding an efficient method to overcome this resistance can improve the clinical effectiveness of this anticancer drug. Unfortunately, the mechanism of cisplatin resistance is a complex biological process involving multiple factors (Chao et al., 1991; Torigoe et al., 2005; Haslehurst et al., 2012; Oiso et al., 2014) and still remains largely unclear.
The induction of apoptosis in cancer cells is thought to be fundamental to the success of the treatment of the disease. The Bcl-2 family members are intimately involved in the apoptosis, but the role of these proteins in drug-induced death is controversial, including anti-apoptotic proteins such as Bcl-2, Bcl-XL, and Bcl-W, and pro-apoptotic proteins such as Bax, Bad, Bid, and Bim (Chu, 1994; Bargou et al., 1995; Tilly et al., 1995; Tao et al., 1997; Hahn et al., 2003; Dumay et al., 2006; Heath-Engel et al., 2008; Tanaka et al., 2010; Chen et al., 2014; Zheng et al., 2015) . It is certain that the Bcl-2 family of proteins is closely related to the regulation of cell death by inducing apoptosis, which is initiated by the release of cytochrome c from mitochondria. However, the relationship between the altered expression of apoptosisregulating proteins and subsequent resistance to apoptosis still needs to be tested and studied.
As a novel potent antitumor candidate targeting thioredoxin reductase (TrxR), Ethaselen (1,2-[bis(1,2-benzisoselenazolone-3(2H)-ketone)]ethane; BBSKE) has shown good antitumor effects in many cancer models (Wang et al., 2012) . It was first prepared by our group and now has entered clinical trial Phase II. Ethaselen was designed to inhibit mammalian TrxR activity by selectively targeting SeCys498/Cys497, the C-terminal active sites of mammalian TrxR, with high binding potential (Shi et al., 2003; Zhao et al., 2006; Xing et al., 2008) . Ethaselen was found to inhibit TrxR activity in several human carcinoma cell lines and tumor-bearing mouse models (Shi et al., 2003; Zhao et al., 2006) . Furthermore, TrxR inactivation by Ethaselen correlates with cell death/apoptosis, including A549 (human lung cancer), HeLa (human cervical cancer), BGC823 (human stomach adenocarcinoma), HL60 and K562 (human leukemia), LoVo (human colon cancer), Bel-7402 (human epithelial hepatoma), and Tca8113 (human tongue cancer) cells (Shi et al., 2003; Zhao et al., 2006; Xing et al., 2008; Fu et al., 2011; Wang et al., 2011; . Moreover, a synergistic effect has been observed in the study of the combination of Ethaselen and cisplatin (CDDP) in vivo. Studies have shown that the antitumor efficacy of cisplatin on the stomach cancer cell line BGC-823, the human lung cancer cell line PG-BE1, the subcutaneous transplanted lung cancer cell line A459 in the nude mice, and the human colon adenocarcinoma cell line LoVo would be further enhanced through synergetic combination with Ethaselen (Tan et al., 2010) . These previous studies have indicated that there is a close link of the antitumor mechanism between Ethaselen and CDDP, suggesting that Ethaselen may be a potential and efficient method for reversing cisplatin resistance.
In the present study, we established cisplatinresistant K562 cells and attempted to clarify the relationship between apoptosis and drug resistance in K562 cells. The expression patterns of the apoptosisregulating proteins were analyzed to elucidate the mechanism of cisplatin-induced resistance. Furthermore, a possible effective way of reversing cisplatin resistance by Ethaselen was studied in order to provide a potential clinical application of Ethaselencisplatin combined chemotherapy.
Materials and methods

Chemicals and antibodies
Ethaselen (Fig. 1 ) was previously synthesized in our lab and verified by high-performance liquid chromatography (HPLC) (Shi et al., 2003) . Ethaselen was dissolved in 20 mmol/L in dimethyl sulfoxide (DMSO). Cyclosporin A (CsA) and 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA) were purchased from Sigma-Aldrich (Shanghai, China), and were dissolved in 5 and 20 mmol/L in HPLC-grade DMSO, respectively. The mammalian protease inhibitor cocktail was bought from Amresco Inc. (Solon, USA). Antibodies against Caspase-3 were purchased from Cell Signaling Technology (Shanghai, China). Antibodies against Bax, Bcl-2, and cytochrome c were bought from Santa Cruz Biotechnology Inc. (Shanghai, China), and β-actin was purchased from OriGene Technologies (Beijing, China).
Cell culture
Human erythrocyte leukemic cell line K562 and K562/CDDP were grown in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) in 5% CO 2 atmosphere at 37 °C. K562/CDDP cells were established in our laboratory by pulsed induction (Du et al., 2007) and exposed to the final concentration of 30 μmol/ml cisplatin for six months.
Cell growth curves and population doubling time
K562, K562/CDDP (without CDDP), and K562/CDDP (exposed to 30 μmol/ml cisplatin) were obtained in the logarithmic phase with a cell density of 2000 cells/ml and seeded into 96-well plates (200 μl/well). MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Amresco Inc., Solon) assay was conducted each day for the next eight days. The cell growth curves were drawn with time as X-axis and the average absorbance of 16 replicates as Y-axis: the population doubling time (DT)=(t-t 0 )× log2/(logN-logN 0 ), where t and t 0 , respectively, represent the time of culture termination and beginning, and N and N 0 represent the numbers of cells at t and t 0 , respectively.
Cell morphology
K562 and K562/CDDP, taken from logarithmic phase cells, were used to observe the cell morphology under a 10×40-fold inverted fluorescence microscope.
Cell growth inhibition assays
Cells in the exponential growth phase were plated into 96-well plates at 5000 cells/well. After exposure to various concentrations of CDDP or Ethaselen separately and in combination (the molar ratio of CDDP to Ethaselen was 10: 1) for 24, 48, and 72 h, the growth inhibition activities of different drug treatments on K562 and K562/CDDP cells were determined using MTT assay. The data were recorded on a microplate reader DNM-9602 (Beijing Perlong New Technology Co., Ltd., Beijing, China) at 570 nm. The inhibitory rate was calculated using the software Origin 7.5 (OriginLab, USA).
Median effect analysis
The combination index (CI) was used to explore the drug interaction in combinations including synergy (CI<0.95), additivity (0.95≤CI≤1.05), or antagonism (CI>1.05).
The CI value was calculated as CI=D 1 /D x1 +D 2 /D x2 , where D 1 and D 2 are the dosages of drugs used in combination to get a certain antitumor effect, respectively, and D x1 and D x2 are the dosages of drugs used separately to get same antitumor effect, respectively.
Flow cytometric analysis of apoptosis and intracellular ROS levels
Cells undergoing apoptosis under various treatment conditions were prepared by the Annexin Vpropidium iodide (PI) apoptosis detection kit according to the manufacturer's instructions.
After exposure to CDDP alone or to the combination of CDDP and Ethaselen, cells were harvested, washed once with ice-cold phosphate buffer saline (PBS), and incubated with DCFH-DA (100 μmol/L final concentration) at 37 °C for 15 min in the dark (Sainz et al., 2003) . Then the cells were washed again and maintained in 1 ml PBS. The reactive oxygen species (ROS) levels were determined using the Guava EasyCyte Plus flow cytometry system (Merck Millipore).
Western blot analysis
After drug treatment, the whole cell lysates of K562 and K562/CDDP cells were prepared by lysing cells in the radioimmunoprecipitation assay (RIPA) buffer (137 mmol/L NaCl, 1 mmol/L ethylene diamine tetraacetic acid (EDTA), 10 mmol/L Tris-HCl (pH 7.4), 0.1% sodium dodecyl sulfate (SDS), 1% (0.01 g/ml) sodium deoxycholate, 1% Triton X-100). Mammalian protease inhibitor cocktail was added to the buffer according to the manufacturer's instructions.
In order to get the cytosolic and mitochondrial fractions, K562 and K562/CDDP cells were suspended in 400 μl of the isotonic buffer (250 mmol/L sucrose, 10 mmol/L Tris-HCl, 1 mmol/L EDTA) including protease inhibitors, and lysed by a tightfitting Dounce homogenizer. The supernatant was obtained by centrifuging the lysate at 1000g for 10 min, and subsequently centrifuged at 17 000g for 15 min to separate the cytosolic fraction and mitochondrial sediment which was further lysed by 150 μl RIPA. Protein concentration was determined by the BCA (bicinchoninic acid) method. The cellular protein sample (50 µg) was subjected to sodium dodecyl sulfate-polyacrylamide gel electropheresis (SDS-PAGE), and the separated proteins were subsequently electrically transferred to a polyvinylidene (PVDF) membrane. The membrane was blocked by nonfat milk and incubated with suitable primary and secondary antibodies. The electrochemiluminescence (ECL) signals were recorded on X-ray films.
Statistical analysis
Data of independent experiments were expressed as mean±standard deviation (SD) and analyzed using a two-tailed t-test. P-values less than 0.05 were considered statistically significant.
Results and discussion
Resistant cells and parental cell growth curves and population doubling time
The growth curves of the parental cell line K562 and resistant cells K562/CDDP without drugs (Fig. 2) indicated that the proliferative capacities of resistant cells K562/CDDP were higher than those of the parental cells K562. When cultured with the drug in the medium to maintain drug resistance, the proliferative capacities of the resistant cells K562/CDDP were lower than those of the parental cells K562 (Fig. 2 and Table 1 ), but there was no significant difference (P>0.05).
Cell morphology
Under a 10×40-fold inverted microscope (Fig. 3) , K562 and K562/CDDP cells were the translucent circular suspension cells. The adhesion of K562 cells was weak, and the cells were dispersed in the medium and less attached to the cell culture flask. The cell volume was small. Compared with K562, the adhesion of K562/CDDP was further decreased while the cell volume increased.
Drug sensitivity testing by MTT method in vitro and median effect analysis
From Fig. 4 , it can be seen that with the increase of drug action time, the effects of CDDP, Ethaselen, and their combinations on the K562 and K562/CDDP cells gradually increased, especially obviously in Figs. 4d-4f . The shapes of dose-response curves of the parental and resistant K562 cells to the same drug or drug combination had some differences, which showed the resistance characteristics of the drugresistant cells. As can be seen from 
Flow cytometric analysis of apoptosis
After treating with the vehicle (control), 50 μmol/L CDDP, and the combination of 1.5 μmol/L Ethaselen and 15 μmol/L CDDP for 48 h, K562/CDDP cells were harvested for apoptosis analysis by an Annexin V-PI detection kit. As can be seen from the results (Figs. 5a  and 5b) , there is only a small increase in the percentage of cells treated with CDDP alone undergoing apoptosis compared to the control (3.96% vs. 3.17%). When cells were treated with Ethaselen and CDDP, a significant increase was observed in the percentage of Annexin V+/PI− cells (Fig. 5c) , indicating an early stage apoptosis induced by the addition of a small amount of Ethaselen. 
Intracellular ROS content detection
As shown in Fig. 6 , the ROS level in K562/ CDDP cells was twice of that in K562 cells. Exposure to CDDP resulted in an increase of the ROS levels in K562, while this increase was not obvious in K562/ CDDP. By using the combination of CDDP and small amounts of Ethaselen, the ROS level further increased in both K562 and K562/CDDP cells, which was significantly different (P<0.05) from that with CDDP treatment alone. These results (Fig. 6) indicate that the degree of tolerance for ROS in K562/CDDP cells and the failure of inducing ROS by CDDP may partly be the cause of cisplatin resistance. In addition, further inducing the increase of ROS will reverse the cisplatin resistance in K562/CDDP cells.
Western blot analysis for the expressions of Bax, Bcl-2, Caspase-3, and cytochrome c in K562 and K562/CDDP cells after different treatments
Release of cytochrome c is associated with the decrease of Bcl-2 and increase of Bax followed by activating Caspase-9 and Caspase-3 (Rossé et al., 1998; Jia et al., 2015) . Compared to K562 cells, as shown in Figs. 7 and 8 , a tiny increase in the expression of Bcl-2 and a small decrease in the expression of Bax in K562/CDDP cells were observed. Western blot analysis revealed that Bax protein level of K562 was significantly increased by CDDP alone compared to K562/CDDP cells, while Bcl-2 protein expression in K562 treated by CDDP alone was significantly suppressed compared to that in K562/CDDP cells (Figs. 7 and 8) . Hence, the increased ratio of Bax to Bcl-2 protein after CDDP treatment, following the cytochrome c release and Caspase pathway activation in K562 cells, was not seen in K562/CDDP cells. This result suggests that the ratio of pro-apoptotic drive to anti-apoptotic drive, as revealed by the ratio of Bax to Bcl-2 protein, may determine the difference in CDDPinduced apoptosis between K562 and K562/CDDP cells. By the combined CDDP-Ethaselen treatment, the ratio of Bax/Bcl-2 was obviously increased, subsequently inducing cytochrome c release from mitochondria to cytosol and Caspase-3 activation in both K562 and K562/CDDP cells. These results indicated that Ethaselen could reverse cisplatin resistance in drugresistant K562 cells via activating the mitochondriamediated intrinsic pathway.
Enhanced mitochondrial membrane permeability by the formation of permeability transition pores, following the cytochrome c release
As mitochondrial membrane permeability (MMP) is enhanced by the formation of permeability transition pores (PTPs), which are triggered by ROS, and CsA (a PTP inhibitor) was used to block the formation of PTPs in this study. As shown in Figs. 9 and 10, whether or not adding CsA, there was no obvious difference in cytochrome c release in K562/CDDP after exposure to CDDP alone, which confirmed that CDDP cannot induce the increase in the ROS level (Fig. 6) , followed by the failure of PTP formation in K562/CDDP cells. The treatment of CDDP and Ethaselen triggered the release of cytochrome c, which was blocked by the treatment with CsA, suggesting that the cytochrome c release depends, at least partially, on the formation of PTPs. This result further confirmed that Ethaselen reversing cisplatin resistance by inducing apoptosis is initiated by the release of cytochrome c from mitochondria, suggesting that the increase in ROS level may directly trigger the formation of PTPs to disrupt mitochondrial membrane integrity in a Bcl-2-independent manner. 
Conclusions
A potent and efficient way to reverse cisplatin resistance in K562/CDDP cells by Ethaselen was observed and confirmed through the 21 times decline of the IC 50 of CDDP in K562/CDDP cells by adding small amounts of Ethaselen. The investigation of apoptosis-related molecules and mitochondrial-functionrelated factors further indicated two possible ways to reverse cisplatin resistance (Fig. 11): 1. Ethaselen can specifically inhibit TrxR activities, resulting in the reduction of nuclear factor κB (NF-κB) activities (Lan et al., 2007) , followed by the upregulation of Bax and downregulation of Bcl-2. The increased ratio of Bax/Bcl-2 subsequently induces cytochrome c release from mitochondria to cytosol and Caspase-3 activation in K562/CDDP cells.
2. The elevated ROS levels in K562/CDDP through the inhibition of TrxR by Ethaselen can trigger the formation of PTPs and then enhance MMP, which further confirms that Ethaselen reversing cisplatin resistance by inducing apoptosis is initiated by the release of cytochrome c from mitochondria in a Bcl-2-independent manner.
Our results shed new light on a comprehensive understanding of the mechanism of CDDP resistance in K562 cells and a better knowledge of the relationship between CDDP resistance and Ethaseleninduced changes of TrxR, ROS, and apoptosis-related molecules, providing an efficient way to reverse cisplatin resistance in drug-resistant K562 cells by Ethaselen. Future studies should be carried out such as observing the reversing effects on some other cells to further confirm our conclusion and exploring the best ratio of Ethaselen and cisplatin in combination treatment to provide a potential clinical application of Ethaselen-cisplatin combined chemotherapy.
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